Myoconda (clarithromycin/clofazimine/rifabutin) - RedHill
RHB-104: "Durable remission weeks 16-52: statistically significant benefit in durable remission on all visits, weeks 16-52, demonstrating an improvement of 100% over placebo"; Crohn's disease (RedHill) - Dec 19, 2019 - Corporate Presentation 
P3 data
https://ir.redhillbio.com/static-files/f465e5e9-5f4d-4f71-9584-b7958715e8d5
 
Dec 19, 2019
 
 
98f186d3-e9fe-4273-8e02-083d903f5da5.jpg

143a46a3-6a5b-4331-9c47-a61823eb1c55.jpg

eb4471ce-55da-4945-a794-4815d87be23c.jpg